Research and Markets: Market Access, Pricing, and Reimbursement News in the First Quarter of 2009

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/e9378b/market_access_pri) has
announced the addition of Decision Resources, Inc.'s new report "Market Access,
Pricing, and Reimbursement News in the First Quarter of 2009" to their offering.

The fourth quarter of 2009 was characterized by a wide range of new pricing and
reimbursement initiatives in the United States but more focused measures in most
of the world's other leading pharmaceutical markets. In the short term, payers
are exerting pressure on manufacturers to reduce their prices. In the long term,
payers will increasingly rely on health technology assessment (HTA) to inform
their coverage decisions.

Get the Answers You Need to Shape Your Strategy

The new U.S. administration has identified health reform as one of its highest
political priorities. How does the government plan to promote easier access to
health insurance? What role will comparative effectiveness research play in the
U.S. pharmaceutical market in future? What measures are under way to create a
regulatory framework for biosimilars?

* The French National Health Authority (HAS) recently published an ambitious
plan of action for 2009-2011. How is the HAS responding to government calls for
increased focus on health economic evaluation? What plans does the authority
have for post marketing research? How does the HAS intend to develop
international collaborations?
* The German government is intensifying its efforts to curb pharmaceutical
spending. What action might the government take if the pharmaceutical industry
fails to exercise voluntary pricing restraint? What progress has been made
toward implementing government initiatives to promote health economic evaluation
and to require a second opinion regarding the use of certain drugs?
* The United Kingdom has been very active in introducing reforms in recent
months. What plans does the government have for U.K. pricing from 2009 through
2013? What new measures will promote faster access to innovative medicines? How
does the government plan to improve coverage of end-of-life treatments?

Scope:

* Issues affecting the pharmaceutical industry in the United States: market
trends in 2008 and projections to 2018; impact of the recession on the
pharmaceutical market; measures to promote easier access to health insurance;
adoption of comparative effectiveness research; legislation to create a
regulatory framework for biosimilars; new attempt to authorize prescription drug
importation.
* Issues affecting the pharmaceutical industry in Europe: expanded role for
France's HAS; government appeal for price restraint in Germany; market trends in
Italy and Spain; measures to promote faster access to innovative medicines in
the United Kingdom.
* Issues affecting the pharmaceutical industry in Japan: market trends; industry
proposal for pricing reform; proposed amendments to the process of repricing
drugs in response to market expansion; publication of new guidelines on the
licensing of biosimilars.

Companies Mentioned:

* Agencia Española de Medicamentos y Productos Sanitarios (AEMPS; Spanish Agency
for Medicines and Health Products)
* Agency for Healthcare Research and Quality (AHRQ)
* Agenzia Italiana del Farmaco (AIFA; Italian Medicines Agency)
* All Wales Medicines Strategy Group (AWMSG)
* America's Health Insurance Plans (AHIP)
* Blue Cross Blue Shield Association (BCBSA)
* Commission de la Transparence (CT;Transparency Commission)
* Commonwealth Fund
* Congressional Budget Offi ce (CBO)
* Dirección General de Farmacia y Productos Sanitarios (DGFPS; General
Directorate of Pharmacy and Health Products)
* European Network for Health Technology Assessment (EUNetHTA)
* European Network for Patient Safety (EUNetPaS)
* GlaxoSmithKline
* Haute Autorité de Santé (HAS; National Health Authority)
* Health Information and Quality Authority
* Takeda
* U.K. Medicines Information (UKMi)
* U.S. Census Bureau
* Verband Forschender Arzneimittelhersteller (VFA; German Association of
Research-Based Pharmaceutical Companies)
* Veterans Health Administration within the Department of Veterans Affairs

For more information visit
http://www.researchandmarkets.com/research/e9378b/market_access_pri

Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009